Novartis antitrust settlement; unique Xiaomi deal; Apple’s new European hire; Brazilian IP office leadership clear out; FTC non-compete policy; plus much more
Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week
The Long Read
UK and European Patent Attorney at EIP, Andrew Thompson, offers insight into the key provisions and IP considerations of the incoming EU CHIPS Act. Read more here
MONDAY 09 January
Novartis’ decision to stump up $245 million kill a series of antitrust allegations marks the latest big money move by pharma firms seeking to settle reverse-payment allegations. Read more here
A dive into Docket Navigator data shows US district courts saw fewer patent cases in 2022, with 3,806 filings – a 5% decline when compared with the previous year. Read more here
TUESDAY 10 January
InterDigital’s chief licensing officer Eeva Hakoranta shares her SEP takeaways of 2022 with IAM. Read more here
Royalty Pharma agreed to buy two IP-backed royalty rights from Ionis Pharmaceuticals for up to $1.1 billion, with $500 million to be handed over upfront. Read more here
A US judge ruled that a class of cell phone purchasers can pursue allegations that Qualcomm closed off the market for certain modem chips through exclusive contracts in violation of California law. Read more here
WEDNESDAY 11 January
Xiaomi inked a ‘unique’ multi-lateral licensing deal with IP Bridge, Orange and Siemens. Read more here
The US Supreme Court put the final nail in the coffin of Juno Therapeutics’ appeal against the invalidation of its CAR-T therapy patent on grounds of inadequate written description. Read more here
THURSDAY 12 January
In the first of a series of weekly columns, former IAM editor-in-chief Joff Wild argues that the patent licensing market is working and regulators should not jump in. Read more here
Apple extends in-house patent team to Europe, reflecting region’s rising importance. Read more here
Brazilian President Luiz Inácio Lula da Silva clears out leadership at the country’s IP office. Read more here
FRIDAY 13 January
IAM looked into what BioNTech’s £362 million AI acquisition says about the future of life sciences IP strategies. Read more here
Here are the key US rulings that patent technical experts must know in 2023. Read more here
Prepare now: call to action for chief IP officers on draft FTC non-compete policy. Read more here
SATURDAY 14 January
Opinion: IAM editor Rachel Mountain reflects on diversity in IP and offers a glimpse into an upcoming special report. Read more here
